Search
GLP-1 Treatment Options
A collection of 63 research studies where GLP-1 is the interventional treatment. These studies are located in the United States. GLP-1 is used for conditions such as Obesity, Type 2 Diabetes and Myocardial Infarction.
1 - 12 of 63
Match to Clinical Trials
Access to cutting-edge treatments
Latest clinical trials
Find trials in your area
Search by Name
Filter by Condition
Filter by Age
Filter by Type
Gender
Type of Study
Clinical Trial Phase
Featured Offer
Lose Weight with GLP-1 Medications
Recruiting
Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $100 off your first program with code policy-lab-100.
Conditions:
Overweight
Overweight and Obesity
Obesity
Weight Loss
Morbid Obesity
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Chronic Cough Research Study
Recruiting
Are you tired of living with chronic cough? Our research study is now looking to enroll people from all backgrounds to help research potential new treatment options for chronic cough.
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
You are under no obligation to take part and health insurance is not required. Find out more today! We’d love to hear from you!
Conditions:
Chronic Cough
Refractory or Unexplained Chronic Cough
Cough
Asthma
Sinusitis
Featured Trial
Dilated Cardiomyopathy (DCM) Research Study
Recruiting
If you are identified as eligible for investigational genetic testing, you will be sent a saliva collection kit to your home. Once you have completed and returned your kit to Sano Genetics, your sample will be tested for a specific genetic pathway called BAG3.
Investigational genetic testing can help you better understand your body and its needs, as well as how DCM may be passed down in your family. Those who are identified as having a variant in the BAG3 gene will be referred to an upcoming clinical trial.
Investigational genetic testing can help you better understand your body and its needs, as well as how DCM may be passed down in your family. Those who are identified as having a variant in the BAG3 gene will be referred to an upcoming clinical trial.
Conditions:
Dilated Cardiomyopathy (DCM)
Cardiovascular Diseases
Cardiomyopathy
Cardiovascular Disease
Heart Failure
Effect of GLP-1 on Postprandial Lipid Metabolism
Unknown
Individuals with obesity have an increased risk for heart disease and diabetes. There are current drugs on the market that target the hormone, Glucagon like peptide-1 (GLP-1) to treat diabetes. The investigators want to determine if targeting this hormone will also help people with high cholesterol and triglycerides. In this study, the investigators are looking at the role of GLP-1 in healthy subjects and subjects that have had bariatric surgery.
Gender:
ALL
Ages:
Between 40 years and 60 years
Trial Updated:
01/02/2013
Locations: Veteran's Affairs Clinical Research Unit, Cincinnati, Ohio
Conditions: Heart Disease
A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease
Completed
The primary purpose of study is to estimate the incidence and comparative effect on health outcomes: 1) hospitalization for heart failure, 2) below knee lower extremity amputation. The date of first exposure to the particular drug(s) in the database, where the exposure start is between 1-April-2013 to 15-May-2017 and outcome data for these participants will be analyzed and reported in this study.
Gender:
ALL
Ages:
All
Trial Updated:
06/20/2025
Locations: Janssen Investigative Site, Titusville, New Jersey
Conditions: Diabetes Mellitus, Type 2, Cardiovascular Diseases
Efficacy of GLP-1 Receptor Agonists in Treating Upper and Lower Extremity Lymphedema
Recruiting
Lymphedema affects millions and currently lacks effective drug treatments, relying mainly on compression therapy. Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have shown potential in managing obesity and diabetes, which can worsen lymphedema. Although anecdotal evidence suggests benefits of GLP-1 RAs for lymphedema patients, rigorous prospective studies are lacking. This study aims to evaluate the effectiveness of GLP-1 RAs in improving quality of life and clinical outcomes in lymphedem... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/01/2025
Locations: River Center, Red Bank, New Jersey +1 locations
Conditions: Lymphedema
Effect of GLP-1 Receptor Agonists on Trabecular Bone Score
Terminated
This study will help determine the effect of Glucagon Like Peptide-1 (GLP-1)receptor agonists on bone strength in postmenopausal women with type 2 diabetes mellitus (T2DM)
Gender:
FEMALE
Ages:
55 years and above
Trial Updated:
05/23/2025
Locations: University of Mississippi Medical Center, Jackson, Mississippi
Conditions: Osteoporosis, Postmenopausal, Diabetes Mellitus, Type 2
Identifying Changes in Food Behaviors Associated With Beginning GLP-1 Medication
Not Yet Recruiting
In recent years, GLP-1 medications have become a widely employed approach by physicians to address weight concerns in patients and lead to weight loss. Little is known, however, about how these medications may alter an individual's attitude towards food, food reactivity, or the specific types and amounts of foods an individual will choose. The purpose of this study is to observe the changes an individual experiences in their relationship and reaction to food and in their food selection prior to... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/15/2025
Locations: Health, Ingestive Behavior, and Technology Laboratory of Pennsylvania State University, State College, Pennsylvania
Conditions: Weight Loss, Food Selection
GLP-1 RA on Liver OMICS in MASLD
Not Yet Recruiting
In patients with type II diabetes mellitus (T2DM) and obesity, an excess plasma-free fatty acid is found with an associated increased lipid accumulation in adipocytes and liver tissue. Lipid droplet accumulation in the hepatocytes is an initial step in the development of metabolic dysfunction associated steatotic liver disease (MASLD. Insulin resistance, which is associated with T2DM, mediates the inflammation of these lipids, resulting in the progression of MASLD to metabolic dysfunction associ... Read More
Gender:
ALL
Ages:
Between 18 years and 80 years
Trial Updated:
05/13/2025
Locations: Froedtert Hospital, Milwaukee, Wisconsin
Comparative Effectiveness of Empagliflozin in the US
Active Not Recruiting
Empagliflozin, a sodium glucose co-transporter 2 (SGLT-2) inhibitor, was launched as a treatment for type 2 diabetes mellitus (T2DM) in the U.S. in August 2014. In contrast with several previous cardiovascular outcomes trials, which failed to demonstrate an association with a higher or a lower risk of cardiovascular outcomes associated with members of other recently marketed antidiabetic classes, the EMPA-REG OUTCOME trial has shown that patients at high cardiovascular risk randomized to empagli... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/12/2025
Locations: Bringham Women Hospital, Boston, Massachusetts
Conditions: Diabetes Mellitus, Type 2
Protective Benefits of a Clear Liquid Diet on Residual Gastric Content in Patients Taking Glucagon Like Peptide-1 Receptor (GLP-1 RA) Agonist Prior to Anesthesia
Not Yet Recruiting
The purpose of this study is to determine if prolonged fasting from solids and transitioning to a CLD for 24 hours is protective to decrease RGC in patients on GLP-1 RAs presenting for upper endoscopy, to determine if prolonged fasting is associated with increased thirst, hunger and anxiety, To determine if signs and symptoms of nausea, vomiting, retching, abdominal bloating, and abdominal pain are present on the day of surgery, to see if there is any variability between preoperative gastric ult... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
04/02/2025
Locations: The University of Texas Health Science Center at Houston, Houston, Texas
Conditions: Pulmonary Aspiration
Bone Metabolism in 12-21 Year Olds Undergoing GLP-1 Receptor Agonist Therapy
Not Yet Recruiting
The goal of this clinical trial is to compare bone health markers over 24 months in participants 12 - 21 years of age with obesity who are starting the glucagon-like peptide-1 (GLP-1) Semaglutide as compared to those with similar weight followed by lifestyle management.
Participants will:
* Take Semaglutide as prescribed or continue to work on lifestyle management for weight loss
* Take provided calcium and vitamin D supplements
* Attend 6 study visits over 24 months with two at the beginning... Read More
Gender:
ALL
Ages:
Between 12 years and 21 years
Trial Updated:
03/31/2025
Locations: University of Virginia Medical Center, Charlottesville, Virginia
Conditions: Obesity in Children, Bone Strength, GLP - 1, Lifestyle Modification, Bone Density, Obesity
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
Recruiting
RYGB (roux-en-y gastric bypass) has been reported to reverse type 2 diabetes (T2DM) immediately after surgery before any significant weight loss. In addition, a growing number of patients have been recognized with life-threatening hyperinsulinemic hypoglycemia several years following their surgery. While the mechanisms by which RYGB improves glucose metabolism or alters islet cell function in patients after RYGB are not understood, recent studies suggest that increased secretion of GI hormones,... Read More
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
02/12/2025
Locations: Texas Diabetes Institute - University Health System, San Antonio, Texas +1 locations
Conditions: Post Bariatricsurgery, Hypoglycemia
GLP-1 Analogue Effects on Food Cues, Stress, Motivation for Highly Palatable Foods, and Weight
Completed
To examine response to a glucagon-like peptide-1 analogue vs. placebo in patients with obesity and assess impact on craving, hunger, stress, and weight outcomes.
Gender:
ALL
Ages:
Between 18 years and 55 years
Trial Updated:
02/10/2025
Locations: The Yale Stress Center: Yale University, New Haven, Connecticut
Conditions: Obesity
Beta-cell Response to Incretin Hormones in Cystic Fibrosis
Recruiting
In recent years, diabetes has emerged as one of the most significant co-diseases that many Cystic Fibrosis (CF) patients develop. Type 1 (T1D) and Type 2 (T2D) diabetes results when either the body does not make enough insulin or the body does not respond correctly to this insulin, respectively. Insulin is a hormone which is made by cells in the pancreas and helps carry glucose (sugar) from the food we eat to the cells of the body for energy. While cystic fibrosis related diabetes (CFRD) has man... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/28/2025
Locations: Children's Hospital of Philadelphia and University of Pennsylvania, Philadelphia, Pennsylvania
Conditions: Cystic Fibrosis, Pancreatic Insufficiency
1 - 12 of 63